Nendocabtagene onogedleucel

N/A

Report date: 2025/05/23 14:38:44

Base Information

Drug NameNendocabtagene onogedleucel
Drug Alias NameAnti-BCMA AlloCAR T (Allogene Therapeutics)Anti-BCMA CAR T cell therapy (Allogene Therapeutics)UCARTBCMA (Allogene Therapeutics)ALLO-715
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellectis Sa
China Registration ClassN/A

Develop Information

Active CompaniesAllogene Overland BiopharmAllogene Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A